share_log

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $80

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $80

HC Wainwright & Co.维持对Celldex Therapeutics的买入,将目标股价提高至80美元
Benzinga ·  2023/11/06 11:09

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $73 to $80.

HC Wainwright & Co. 分析师约瑟夫·潘吉尼斯维持Celldex Therapeutics(纳斯达克股票代码:CLDX)的买入,并将目标股价从73美元上调至80美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发